Propofol

BEAS2B or NSCLC cells (1  ×  10⁴ cells/well) were plated into 96‐well plates overnight. Next NSCLC cells were treated with AS-IV (0, 5, 10, 20, or 40 ng/mL) [21 (link)] and/or propofol (0, 2.5, 5, 10, or 20 μg/mL) [23 (link)] for 48 h. After that, each well was supplemented with CCK-8 reagent (10 µL; Beyotime), and the cells were then incubated for 2 h. Finally, the absorbance at 450 nm was measured with a microplate reader (DR-200Bs, Diatek). AS-IV and propofol were obtained from Sigma-Aldrich (PHL89377 and Y0000016, Sigma-Aldrich, St Louis, USA).

H9c2 cells were incubated with a normal medium in a cell incubator for 24 h. Cells were then exposed to hypoxic conditions (oxygen deprivation, 1% O₂) for 24 h in a culture medium with lower glucose and 1% FBS. After hypoxia, the cells were oxygenated under a normal oxygen concentration (reoxygenation) for 24 h in a normal medium. According to the previous study, propofol (Sigma-Aldrich, United States) was added respectively to the cells 1 h before and during the hypoxia-reoxygenation with different concentrations (5, 10, and 20 μM) (Zhao et al., 2015 (link)). U0126 (Beyotime, Haimen, China), MEK1/2 inhibitor, was added to the cells during OGD/R at a concentration of 20 μM. After H9c2 cells were incubated with a normal medium in cell incubator for 24 h, propofol and caspase inhibitor Z-VAD-FMK (Beyotime, Haimen, China) were respectively added to the cells for 24 h.